Newsroom
Featured News
- Investors10 January 2025
Lotus Achieves Historical High with Unaudited 2024 Revenue of NT$18.6 Billion
- Business07 January 2025
Lotus Announces the Closing of the Alphachymotrypsine Choay® Acquisition, Ready to consolidate revenue from Q1 2025
- Investors10 December 2024
Lotus Reported Unaudited November Revenues of NT$1,061 million, YTD Revenue Surpassing the Total Revenue for 2023
- Investors07 November 2024
Lotus Reported Unaudited October Revenues of NT$1,885 million
- Investors07 November 2024
Lotus Achieves Second-Highest Quarterly Performance in Company History with 3Q24 Financial Results
- Investors06 November 2024
Lotus pharmaceuticals 3Q24 earnings call
- Business30 October 2024
Lotus Pharmaceutical's novel drug Zepzelca® (lurbinectedin) has demonstrated significantly superior efficacy in First-line maintenance therapy for Small Cell Lung Cancer (ES-SCLC) when combined with Atezolizumab
- Investors11 October 2024
Lotus Reported Unaudited September Revenues of NT$1,187 million
- Investors10 September 2024
Lotus Reported Unaudited August Revenues of NT$1,325 million
